|
US2020253934A1
|
|
Inhibitors of pde6delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders
|
|
WO2016083490A1
|
|
Compounds for the treatment of amyloid-associated diseases
|
|
CN106103439A
|
|
2,7 diaza spiros [3.5] nonane compound
|
|
WO2015140130A1
|
|
Oxadiazole compounds
|
|
EP2744798A1
|
|
Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease
|
|
WO2013004642A1
|
|
1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases
|
|
GB0814849D0
|
|
Clastogenicity testing
|
|
EP2188272A2
|
|
Phenyl- and benzylthiazolylpiperazine derivatives for the treatment of neurodegenerative diseases
|
|
GB0715192D0
|
|
Heterocyclyl-substituted thiadiazole derivatives for the treatment of neuro degenerative diseases
|
|
GB0715256D0
|
|
Benzylthiazolypiperazine derivatives for the treatment of neuro degenerative diseases
|
|
GB0715253D0
|
|
Aromatic derivatives for the treatment of neuro degenerative diseases
|
|
GB0715260D0
|
|
Thiadiazole derivatives with aliphatic sulfonamidopiperazinyl substiti for the treatment of neuro degenerative diseases
|
|
GB0715227D0
|
|
Thiadiazolypiperazine derivitives for the treatment of neuro degenerative diseases
|
|
GB0715255D0
|
|
Thiadiazol-piperazinyl derivatives for the treatment of neurodegenerative diseases
|
|
GB0715257D0
|
|
Phenylthiazolylpiperazine derivatives for the treatment of nuero degenerative diseases
|
|
GB0623258D0
|
|
Thiadiazole derivatives for the treatment of neuro-degenerative diseases
|
|
GB0610792D0
|
|
Methods and tools for the screening of factors affecting protein misfolding
|
|
GB0602335D0
|
|
Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
|
|
WO2005005640A1
|
|
A yeast model for amyloidogenic protein toxicity
|
